Reagents and instruments for immunology, cell biology and molecular biology.
 
> Rutaecarpine [84-26-4]

Rutaecarpine [84-26-4]

Print Print
Please log in

Cat# HY-N0147-10mg

Size : 10mg

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC50 value of 0.28 μM.

For research use only. We do not sell to patients.

Rutaecarpine Chemical Structure

Rutaecarpine Chemical Structure

CAS No. : 84-26-4

This product is a controlled substance and not for sale in your territory.

Based on 5 publication(s) in Google Scholar

Other Forms of Rutaecarpine:

  • Rutaecarpine (Standard) Get quote

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3
Description

Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC50 value of 0.28 μM.

IC50 & Target[1]

COX-2

0.28 μM (IC50, in BMMC)

COX-1

8.7 μM (IC50, in BMMC)

Cellular Effect
Cell Line Type Value Description References
CCD-18Co IC50
> 50 μM
Compound: 1
Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
CCD-841CoN IC50
> 50 μM
Compound: 1
Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
HCT-116 IC50
31.1 μM
Compound: 1
Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
HCT-15 IC50
> 50 μM
Compound: 1
Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
HEK293 EC50
2.06 μM
Compound: 2
Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of channel current at -60 mV holding potential by whole-cell patch-clamp method
Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of channel current at -60 mV holding potential by whole-cell patch-clamp method
[PMID: 27159637]
HeLa EC50
26.1 μM
Compound: 1a
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 28958621]
LS174T IC50
6.1 μM
Compound: 1
Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
RKO IC50
> 50 μM
Compound: 1
Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
SW480 IC50
> 50 μM
Compound: 1
Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
[PMID: 35544614]
In Vitro

Rutaecarpine has shown a variety of intriguing biological properties such as anti-thrombotic, anticancer, anti-inflammatory and analgesic, anti-obesity and thermoregulatory, vasorelaxing activity, as well as effects on the cardiovascular and endocrine systems[2]. Rutaecarpine inhibits COX-2 and COX-1 dependent phases of PGD2 generation in BMMC in a concentration-dependent manner with an IC50 of 0.28 μM and 8.7 μM, respectively. It inhibits COX-2-dependent conversion of exogenous arachidonic acid to PGE2 in a dose-dependent manner by the COX-2-transfected HEK293 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rutaecarpine Related Antibodies
In Vivo

Rutaecarpine showed in vivo anti-inflammatory activity on rat l-carrageenan induced paw edema by intraperitoneal administration[1]. Rutaecarpine significantly decreases the number of antibody-forming cells and causes weight decrease in spleen in a dose-dependent manner. In addition, rutaecarpine administered mice exhibit reduced splenic cellularity, decreased numbers of total T cells, CD4+ cells, CD8+ cells, and B cells in spleen. IL-2, interferon and IL-10 mRNA expressions are suppressed significantly by rutaecarpine treatment. The number of CD4+IL-2+ cells is reduced significantly following administration of mice with rutaecarpine[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

287.32

Formula

C18H13N3O
CAS No.

84-26-4
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1N2C(C(NC3=C4C=CC=C3)=C4CC2)=NC5=C1C=CC=C5
Structure Classification
  • Alkaloids
  • Indole Alkaloids
Initial Source
  • Plants
  • Rutaceae
  • Evodia rutaecarpa (Juss.) Benth.
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (174.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4804 mL 17.4022 mL 34.8044 mL
5 mM 0.6961 mL 3.4804 mL 6.9609 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.00%

SDS (251 KB)

COA (253 KB) LCMS (269 KB)

Handling Instructions (2659 KB)
References

  • [1]. Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999 Dec;48(12):621-5.  [Content Brief]

    [2]. Lee SH, et al. Progress in the studies on rutaecarpine. Molecules. 2008 Feb 6;13(2):272-300.  [Content Brief]

    [3]. Jeon TW, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice. Toxicol Lett. 2006 Jul 1;164(2):155-66.  [Content Brief]

Cell Assay
[1]

Rutaecarpine is dissolved in DMSO and diluted with appropriate medium before use. COX-1 and COX-2 cDNA-transfected HEK293 cells are prepared. For measuring inhibitory activity on COX-1 and COX-2 by rutaecarpine, cells in 1 mL of culture medium are seeded into each well of 24-well. After culture for 4 days, the supernatants are removed and 250 mL of fresh medium is added to the cells with or without rutaecarpine. After preincubation for 5 h at 37°C, the cells are further incubated at 37°C for 30 min with 50 mM arachidonic acid. All reactions are stopped by centrifugation at 120 g at 4°C for 5 min. Concentrations of PGE2 in the supernatant are measured[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1][3]

Rats: Rutaecarpine is dissolved in 0.1% carboxymethyl cellulose and diluted with appropriate medium before use. Male Splague-Dawley (SD) rats (180-220 g) are used in the study. Rutaecarpine administered intraperitoneally and, 1 h later, l-carrageenan solution is injected to right hind paw of rats. Paw volumes are measured using plethysmometer 5 h after l-carrageenan injection[1].

Mice: For the antibody response to SRBCs, rutaecarpine is administered at a single dose of 10 mg/kg, 20 mg/kg, 40 mg/kg or 80 mg/kg in 10 mL of 1% povidone solution intravenously. Control animals are given 1% povidone solution at 10 mL/kg. Specific pathogen-free female BALB/c mice are used in the study[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References

  • [1]. Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999 Dec;48(12):621-5.  [Content Brief]

    [2]. Lee SH, et al. Progress in the studies on rutaecarpine. Molecules. 2008 Feb 6;13(2):272-300.  [Content Brief]

    [3]. Jeon TW, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice. Toxicol Lett. 2006 Jul 1;164(2):155-66.  [Content Brief]

  • [1]. Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999 Dec;48(12):621-5.

    [2]. Lee SH, et al. Progress in the studies on rutaecarpine. Molecules. 2008 Feb 6;13(2):272-300.

    [3]. Jeon TW, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice. Toxicol Lett. 2006 Jul 1;164(2):155-66.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.4804 mL 17.4022 mL 34.8044 mL 87.0110 mL
5 mM 0.6961 mL 3.4804 mL 6.9609 mL 17.4022 mL
10 mM 0.3480 mL 1.7402 mL 3.4804 mL 8.7011 mL
15 mM 0.2320 mL 1.1601 mL 2.3203 mL 5.8007 mL
20 mM 0.1740 mL 0.8701 mL 1.7402 mL 4.3505 mL
25 mM 0.1392 mL 0.6961 mL 1.3922 mL 3.4804 mL
30 mM 0.1160 mL 0.5801 mL 1.1601 mL 2.9004 mL
40 mM 0.0870 mL 0.4351 mL 0.8701 mL 2.1753 mL
50 mM 0.0696 mL 0.3480 mL 0.6961 mL 1.7402 mL
60 mM 0.0580 mL 0.2900 mL 0.5801 mL 1.4502 mL
80 mM 0.0435 mL 0.2175 mL 0.4351 mL 1.0876 mL
100 mM 0.0348 mL 0.1740 mL 0.3480 mL 0.8701 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rutaecarpine Related Classifications

  • Inflammation/Immunology Cancer
  • Cancer Targeted Therapy Cancer Immunotherapy
  • Immunology/Inflammation
  • COX
Help & FAQs

Keywords:

Rutaecarpine84-26-4RutecarpineCOXCyclooxygenaseInhibitorinhibitorinhibit